Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 31, 2001
Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and manA Abelö, J Gabrielsson, B Holstein, et al.Acta Radiologica (Stockholm, Sweden : 1987)|September 1, 1987
Comparison of ionic and non-ionic nitroxide spin labels for urographic enhancement in magnetic resonance imagingW Grodd, H Paajanen, U G Eriksson, et al.Biopharmaceutics & Drug Disposition|March 25, 1998
Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drugU G Eriksson, L Renberg, U Bredberg, et al.Magnetic Resonance in Medicine|July 1, 1987
Metabolic fate in the dog of the nitroxide moiety in a compound with potential utility as a contrast agent in MRIU G Eriksson, M D Ogan, C T Peng, et al.International Journal of Clinical Pharmacology and Therapeutics|March 25, 2011
Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjectsS Johansson, M Cullberg, U G Eriksson, et al.Pharmaceutical Research|November 27, 2013
Pharmacokinetics and metabolic fate of two nitroxides potentially useful as contrast agents for magnetic resonance imagingW R Couet, U G Eriksson, T N Tozer, et al.Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosisT C Sarich, J I Osende, U G Eriksson, et al.Thrombosis and Haemostasis|April 2, 1999
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVTH Eriksson, U G Eriksson, L Frison, et al.Pageof 2